Bio-Techne Corporation (TECH)

347.71 +10.51 (+3.12%) At close: 4:00PM EST

Bio-Techne Corporation

614 McKinley Place NE
Minneapolis, MN 55413
United States
612 379 8854
http://www.bio-techne.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 2,300

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Charles R. Kummeth	CEO, Pres & Director	2.86M	20.79M	1960
Mr. James T. Hippel	Exec. VP of Fin. & CFO	1.15M	4.24M	1971
Ms. Brenda S. Furlow	Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer	821.24k	1.88M	1958
Mr. N. David Eansor	Pres of Protein Sciences Segment	1.08M	5.71M	1961
Mr. Kim Kelderman	Pres of Diagnostics & Genomics	972.4k	N/A	1967
David Clair	Sr. Director of Investor Relations & Corp. Devel.	N/A	N/A	N/A
Mr. Gerry Andros	VP of Sales and Marketing	N/A	N/A	N/A
Mr. Struan Robertson	VP of HR	N/A	N/A	N/A
Mr. Robert M. Gavin	Sr. VP of Analytical Solutions Division	N/A	N/A	1968
Mr. Kevin S. Gould	Sr. VP of Diagnostics Reagents Division	N/A	N/A	1966

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Corporate Governance

Bio-Techne Corporation’s ISS Governance QualityScore as of December 1, 2020 is 1. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.